XML 207 R161.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) € in Millions, $ in Millions | 12 Months Ended |
--- | --- | ---
Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2022 USD ($)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | € 779 | € 714 | € 605 |
New transactions | 0 | 156 | 360 |
Payments made | (167) | (136) | (258) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 114 | 5 | (4) |
Other movements | 0 | 0 | (14) |
Currency translation differences | (17) | 40 | 25 |
Ending balance | 709 | 779 | 714 |
Non-current liabilities related to business combinations and to non-controlling interests | 501 | 674 | 577 |
Current liabilities related to business combinations and to non-controlling interests | 208 | 105 | 137 |
Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | 26 | 59 | 104 |
New transactions | 0 | 0 | 0 |
Payments made | (21) | (29) | (31) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | (5) | (9) | (18) |
Other movements | 0 | 0 | 0 |
Currency translation differences | 0 | 5 | 4 |
Ending balance | 0 | 26 | 59 |
MSD contingent consideration (European vaccines business) |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | 204 | 269 | 312 |
New transactions | 0 | 0 | 0 |
Payments made | (77) | (79) | (75) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 0 | 14 | 26 |
Other movements | 0 | 0 | 0 |
Currency translation differences | 0 | 0 | 6 |
Ending balance | 127 | 204 | 269 |
Shire contingent consideration arising from the acquisition of Translate Bio |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | 380 | 354 | 0 |
New transactions | 0 | 0 | 323 |
Payments made | 0 | 0 | 0 |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 74 | 2 | 19 |
Other movements | 0 | 0 | 0 |
Currency translation differences | (13) | 24 | 12 |
Ending balance | 441 | 380 | 354 |
Amunix |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | 165 | 0 | 0 |
New transactions | 0 | 156 | 0 |
Payments made | (69) | 0 | 0 |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 45 | (2) | 0 |
Other movements | 0 | 0 | 0 |
Currency translation differences | (4) | 11 | 0 |
Ending balance | 137 | 165 | 0 |
Other |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | 4 | 32 | 189 |
New transactions | 0 | 0 | 37 |
Payments made | 0 | (28) | (152) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 0 | 0 | (31) |
Other movements | 0 | 0 | (14) |
Currency translation differences | 0 | 0 | 3 |
Ending balance | € 4 | € 4 | € 32 |
Translate Bio |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Contingent consideration liabilities | $ |  |  |  | $ 382

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2023-01-01 -Paragraph 93 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent consideration liabilities. + References No definition available. + Details
Name: | sny_ContingentConsiderationLiabilities
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease through net exchange differences business combinations and noncontrolling interests. + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |